Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : GlaxoSmithKline
Femme et Homme Max 99 ans
GlaxoSmithKline
MAJ Il y a 4 ans
Immunogenicity and safety study of one dose of GSK Biologicals? meningococcal conjugate vaccine (GSK134612) in healthy adolescents aged 10 to 15 years. Estudio de inmunogenicidad y seguridad de la vacuna conjugada meningocócica de GSK Biologicals (GSK134612) en adolescentes sanos de 10 a 15 años de edad
To evaluate the vaccine response induced by one dose of MenACWY-TT administered to MenC-primed and MenC unprimed subjects. Evaluar la respuesta vacunal inducida por una dosis de la vacuna MenACW...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
Study of a new drug’s effect in people with severe rheumatoid arthritis who have not responded sufficiently well to treatment with DMARDs
To assess the efficacy of GSK3117391 in subjects with severe RA
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
Evaluate a Vaccine against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox Valutare un vaccino contro la Varicella e un vaccino combinato contro 4 malattie virali infantili:Morbillo, Parotite, Rosolia e Varicella
Co-primary objectives Phase A Efficacy: To demonstrate the efficacy of one dose of Varilrix in preventing confirmed varicella cases over at least two years after vaccination. OR/AND To demonstrate t...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A two-part trial to evaluate the safety, tolerability, clinical effect and the potential to enter through the skin into the blood stream of topically applied GSK2981278 ointment in subjects with plaque psoriasis
Part A -To evaluate the safety and tolerability of topically applied GSK2981278 in subjects with plaque psoriasis -To evaluate the systemic exposure of GSK2981278 following topical application i...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A 12 month study to compare FF/UMEC/VI with FF/VI and UMEC/VI in patients with Chronic Obstructive Pulmonary Disease(COPD) and a history of COPD exacerbation 12 kuukautta kestävä lääketutkimus, jossa verrataan kolmea eri yhdistelmävalmistetta sellaisten keuhkoahtaumatautia sairastavien potilaiden hoidossa, joilla on ollut vähintään yksi keuhkoahtaumataudin pahenemisvaihe
To evaluate the efficacy of FF/UMEC/VI to reduce the annual rate of moderate and severe exacerbations compared with dual therapy of FF/VI or UMEC/VI in subjects with COPD.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A phase IV, single-blinded, randomized, single centre study to demonstrate the non-inferiority of immunogenicity elicited by GSK Biologicals’ hepatitis B vaccine, Engerix-B in multidose presentation to that elicited by Engerix-B in monodose presentation when administered according to 0, 1, 6 months schedule in healthy adults aged equal to or above 18 years
To demonstrate non-inferiority of multidose Engerix™-B to monodose Engerix™-B in terms of anti-HBs seroprotection rate elicited one month after complete vaccination course (i.e. at Month 7).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A phase IV, open, non-randomized, multicentre study to assess the reactogenicity and immunogenicity of a booster dose of GSK Biologicals’ combined reduced-antigen-content diphtheria, tetanus and acellular pertussis vaccine dTpa (Boostrix™) when administered in healthy adult subjects, after previous booster vaccination with dTpa in study 263855/029 (dTpa-029)
•To assess the persistence of anti-diphtheria, anti-tetanus, anti-PT, anti-FHA, and anti-PRN antibodies 8.5 and 10 years after the previous booster dose in study 263855/029 (dTpa-029). •To assess the ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline, S.A
MAJ Il y a 4 ans
A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre, Long-Term Study to Evaluate the Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 52 Weeks in Adult and Adolescent Subjects with Perennial Allergic Rhinitis
The primary objective of this study is to assess the safety and tolerability of 12 months treatment with intranasal GW685698X 100mcg once daily (QD) in subjects >=12 years of age with PAR.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 4 ans
A randomised, double-blind, placebo-controlled, parallel group study to investigate the safety, tolerability, pharmacokinetics and effect on synovial thickness and vascularity of 28 days repeat dosing of GW274150 or 7.5mg prednisolone in RA subjects
To investigate the effect of GW274150 on synovial vascularity after 28 days repeat dosing
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A Phase II study to demonstrate the benefit of a new kind of anti-cancer treatment (PRAME Immunotherapy) for patients with a certain type of lung cancer, after removal of their tumor
The primary objective of this study is to evaluate the clinical efficacy of the PRAME ASCI versus placebo in terms of Disease-Free Survival (DFS).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
3
4
5
6
7
8
9
10
11
12
Suivant